An inhibitor of type X sPLA2
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

LY433771

Item No. 35406

Technical Information
Formal Name
2-[[5-(aminocarbonyl)-9-(cyclohexylmethyl)-9H-carbazol-4-yl]oxy]-acetic acid
CAS Number
220862-64-6
Synonyms
  • LSN433771
Molecular Formula
C22H24N2O4
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMF: 3 mg/mlDMSO: 3 mg/ml
λmax
227, 250, 291, 346 nm
SMILES
NC(C1=C2C3=C(OCC(O)=O)C=CC=C3N(CC4CCCCC4)C2=CC=C1)=O
InChi Code
InChI=1S/C22H24N2O4/c23-22(27)15-8-4-9-16-20(15)21-17(10-5-11-18(21)28-13-19(25)26)24(16)12-14-6-2-1-3-7-14/h4-5,8-11,14H,1-3,6-7,12-13H2,(H2,23,27)(H,25,26)
InChi Key
XQHXEBCEJGFYFD-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    LY433771 is an inhibitor of type X secretory phospholipase A2 (sPLA2; IC50 = 3 nM).1

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ono, T., Ueno, M., and Hanasaki, K. V type and/or x type sPLA2 inhibitors. (2001).